DB06114InvestigationalSmall molecule
PGX-100 is an intravenous dosage form of modified heparin. It is developed for treatment of exacerbation of obstructive pulmonary disease (COPD) and for the prevention and treatment of cardiac ischemia... It is a nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity.
- Primary indication
- Investigated for use/treatment in cardiac ischemia and cardiac reperfusion injury.Curator reviewed
- Code names
- PGX-100
What you can answer from here — as of April 02, 2025
Which companies are running trials of PGX-100, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account